• Moleculin Biotech announced pooled cardiac safety results for its lead drug candidate Annamycin will be presented in a poster session at the 2026 ASCO Annual Meeting on May 30.
• The analysis across multiple completed clinical trials found no evidence of drug-induced heart damage, supporting use at high cumulative exposure levels.
• The dataset included patients treated for acute myeloid leukemia or soft tissue sarcoma.
• The update supports the company’s ongoing pivotal Phase 2b/3 MIRACLE trial in acute myeloid leukemia, where Annamycin is being developed as an anthracycline option without traditional cumulative dose limits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211702PRIMZONEFULLFEED9725044) on May 21, 2026, and is solely responsible for the information contained therein.